Medical Developments International (MVP) Q1 2027 TU earnings summary

Executive summary

• Q1 FY27 revenue was $10.2m, down $0.7m YoY; operating cash use improved to $0.3m from $0.8m as supplier and employee payments fell.

• European Penthrox demand strengthened, supported by paediatric approval; Australian hospital volumes also grew, while lower prior-period stocking weighed on some market volumes.

Financial highlights

• Revenue was $10.2m, $0.7m below the prior corresponding period (pcp).

• Customer receipts were $9.7m, down $1.5m YoY; lower Penthrox volumes contributed to the decline.

• Supplier and employee payments were $10.1m versus $12.1m pcp, reflecting lower inventory purchases; payments included FY26 annual short-term cash incentives.

• Operating cash outflow was $0.3m, improving from $0.8m pcp; quarter-end cash was $20.6m.

Outlook and guidance

• FY27 expectations: higher in-market Penthrox demand, supported by Europe's paediatric indication and published health-economic data; stable Respiratory demand.

• FY26 Penthrox inventory-stocking benefits are not expected to recur in FY27.

• Amortisation expense of ~ $1m expected for capitalised registration costs for the European paediatric indication.